NOVANTA INC 10-Qquarter ended 2026-10-02

Executive Summary

Novanta earns revenue by selling precision components and technologies to medical and advanced-industrial equipment manufacturers. Its acquisition of Riverpoint Medical expands its position in minimally invasive surgical consumables, alongside investments in robotics, automation and precision manufacturing. Q3 showed accelerating industrial growth, but acquisition costs, amortization and financing expenses overwhelmed the benefit of higher sales. For investors, the opportunity is a broader surgical business and improving automation profitability; the test is whether those gains justify the acquisition’s leverage, dilution and integration burden.

What's Happening in the Business

Riverpoint changes Novanta’s scale and product mix. Acquired on 7/23/2026 for $1.20B net of cash acquired, it contributed $32.9M of Q3 revenue—more than half the consolidated revenue increase. Its surgical consumables complement Novanta’s surgical, imaging and operating-room technologies. However, Riverpoint recorded a $2.3M pretax loss, including acquired-intangible amortization and milestone-payment accretion.

The underlying businesses followed different paths. Automation Enabling Technologies benefited from end-market demand, new products, pricing and cost improvements. Medical Solutions’ acquisition-excluded growth slowed to 3.5% in Q3 vs 6.2% for 9M, while Precision Medicine sales contracted in the quarter. Riverpoint therefore strengthened reported medical growth without resolving the slower growth elsewhere.

Management is regionalizing manufacturing and consolidating sites to improve efficiency. The 2025 restructuring program is expected to be substantially complete by Q1 2027, but duplicate factory costs are currently weighing on medical margins. Planned FY2026 capital spending of $30M–$40M includes a significant China capacity expansion.

Key Financial Highlights

Q3 and 9M ended 10/2/2026; changes are Y/Y unless stated otherwise.

• Product drivers: Advanced Surgical Technologies revenue reached $102M, +66%, including Riverpoint. Robotics and Automation generated $94.0M, +17%, while Precision Manufacturing reached $51.4M, +14%. Precision Medicine fell 5.4% to $57.5M, despite 5.5% growth for 9M.
• Margin divergence: Automation’s Q3 gross margin reached 50.2% vs 47.3%, supported by volume, pricing and efficiency. Medical’s fell to 39.9% vs 43.0%, reflecting acquisition amortization and manufacturing-transition costs.
• Costs outside segments: Q3 unallocated costs rose 70% to $36.5M, principally from acquisition activity. Restructuring, acquisition and related charges totaled $23.1M vs $6.68M; total amortization reached $21.4M vs $11.2M. The effective tax rate rose to 68.2% from 32.4%, further reducing earnings.
• Acquisition funding: Total debt reached $830M vs $251M at year-end; cash fell 61% to $149M. A further $250M Riverpoint payment is due by 1/8/2027, against $438M of available credit-facility capacity. Leverage was 2.43:1 against a 4.00:1 maximum.
• Dilution: Shares outstanding increased 6.0% since year-end. Mandatory equity-unit settlement adds 4.7M–5.9M shares in 11/2028, making per-share growth harder than company-wide growth.

Risk Assessment

• Acquisition and valuation: Goodwill and other intangibles represent 73% of assets, so weaker Riverpoint growth or integration results could produce substantial impairments.
• Funding and interest rates: The approaching milestone payment exceeds current cash; a 100bp rate increase would add ≈$7.5M to annual pretax interest expense.
• Rare-earth supply: Chinese export-license delays have already disrupted certain Precision Manufacturing and Robotics and Automation shipments for several months, increasing costs and risking customer orders.
• Customer spending: Industrial equipment cycles and potential reductions in federal research funding could weaken orders from industrial, life-sciences and pharmaceutical customers.

This 10-Q lists only the risk factors that changed since the annual report. Full list: the company's 10-Ks on SEC.

What to Watch

• Riverpoint integration: Its initial contribution was loss-making after acquisition accounting. Subsequent filings should show whether surgical growth translates into profitability or remains burdened by integration costs and amortization.
• Automation momentum: Acquisition-excluded growth accelerated to 16% in Q3 from 11.5% for 9M. Sustained sales and margin gains would validate product investment; export restrictions or weaker equipment demand could interrupt that progress.
• Manufacturing transition: Management expects substantial completion of the 2025 restructuring program by Q1 2027. Improving medical margins would support the efficiency thesis; persistent duplicate costs would weaken it.
• Milestone funding: Watch how the approaching Riverpoint payment is financed and whether subsequent operating cash generation reduces borrowings rather than requiring further equity issuance.